openPR Logo
Press release

Angiotensin Converting Enzyme (ACE) Inhibitors Market is Booming Worldwide By Top Key Players: Abbott Laboratories, Pfizer, Novartis, Merck, Astra Zeneca, Jhonson and Johnson, Eli Lilly, Sanofi, Bristol-Myers Squibb, Bayer, GSK, Teva Pharmaceutical

09-24-2020 10:38 AM CET | Advertising, Media Consulting, Marketing Research

Press release from: QY Research

Angiotensin Converting Enzyme (ACE) Inhibitors Market

LOS ANGELES, United States: QY Research has recently published a research report titled, “Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Research Report 2020". This report has been prepared by experienced and knowledgeable market analysts and researchers. It is a phenomenal compilation of important studies that explore the competitive landscape, segmentation, geographical expansion, and revenue, production, and consumption growth of the global Angiotensin Converting Enzyme (ACE) Inhibitors market. Players can use the accurate market facts and figures and statistical studies provided in the report to understand the current and future growth of the global Angiotensin Converting Enzyme (ACE) Inhibitors market.

The report includes CAGR, market shares, sales, gross margin, value, volume, and other vital market figures that give an exact picture of the growth of the global Angiotensin Converting Enzyme (ACE) Inhibitors market.

Top Companies/Manufacturers:
Abbott Laboratories, Pfizer, Novartis, Merck, Astra Zeneca, Jhonson and Johnson, Eli Lilly, Sanofi, Bristol-Myers Squibb, Bayer, GSK, Teva Pharmaceutical
Market Segment by Product Type: Sulfhydryl-containing Agents, Dicarboxylate-containing Agents, Phosphonate-containing Agents
Market Segment by Application: , Hypertension, Cardiovascular Diseases, Kidney Diseases, Other
Get PDF Sample Copy of the Report @

https://www.qyresearch.com/sample-form/form/1990583/global-angiotensin-converting-enzyme-ace-inhibitors-market

For Discount, Customization, COVID-19 Impact Analysis in the Report Drop Your Query Here:

https://www.qyresearch.com/customize-request/form/1990583/global-angiotensin-converting-enzyme-ace-inhibitors-market

Buy Now:

https://www.qyresearch.com/settlement/pre/1b281fe80f3a57e33a354478dd811f0d,0,1,global-angiotensin-converting-enzyme-ace-inhibitors-market

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Angiotensin Converting Enzyme (ACE) Inhibitors market.

Key questions answered in the report:

What is the growth potential of the Angiotensin Converting Enzyme (ACE) Inhibitors market?
Which product segment will grab a lion’s share?
Which regional market will emerge as a frontrunner in the coming years?
Which application segment will grow at a robust rate?
What are the growth opportunities that may emerge in the Angiotensin Converting Enzyme (ACE) Inhibitors industry in the years to come?
What are the key challenges that the global Angiotensin Converting Enzyme (ACE) Inhibitors market may face in the future?
Which are the leading companies in the global Angiotensin Converting Enzyme (ACE) Inhibitors market?
Which are the key trends positively impacting the market growth?
Which are the growth strategies considered by the players to sustain hold in the global Angiotensin Converting Enzyme (ACE) Inhibitors market
TOC

1 Angiotensin Converting Enzyme (ACE) Inhibitors Market Overview
1.1 Product Overview and Scope of Angiotensin Converting Enzyme (ACE) Inhibitors
1.2 Angiotensin Converting Enzyme (ACE) Inhibitors Segment by Type
1.2.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Growth Rate Comparison by Type (2021-2026)
1.2.2 Sulfhydryl-containing Agents
1.2.3 Dicarboxylate-containing Agents
1.2.4 Phosphonate-containing Agents
1.3 Angiotensin Converting Enzyme (ACE) Inhibitors Segment by Application
1.3.1 Angiotensin Converting Enzyme (ACE) Inhibitors Sales Comparison by Application: 2020 VS 2026
1.3.2 Hypertension
1.3.3 Cardiovascular Diseases
1.3.4 Kidney Diseases
1.3.5 Other
1.4 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Size Estimates and Forecasts
1.4.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue 2015-2026
1.4.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales 2015-2026
1.4.3 Angiotensin Converting Enzyme (ACE) Inhibitors Market Size by Region: 2020 Versus 2026
1.5 Angiotensin Converting Enzyme (ACE) Inhibitors Industry
1.6 Angiotensin Converting Enzyme (ACE) Inhibitors Market Trends 2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Competition by Manufacturers
2.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Manufacturers (2015-2020)
2.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Share by Manufacturers (2015-2020)
2.3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Average Price by Manufacturers (2015-2020)
2.4 Manufacturers Angiotensin Converting Enzyme (ACE) Inhibitors Manufacturing Sites, Area Served, Product Type
2.5 Angiotensin Converting Enzyme (ACE) Inhibitors Market Competitive Situation and Trends
2.5.1 Angiotensin Converting Enzyme (ACE) Inhibitors Market Concentration Rate
2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue
2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
2.7 Primary Interviews with Key Angiotensin Converting Enzyme (ACE) Inhibitors Players (Opinion Leaders) 3 Angiotensin Converting Enzyme (ACE) Inhibitors Retrospective Market Scenario by Region
3.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Retrospective Market Scenario in Sales by Region: 2015-2020
3.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Retrospective Market Scenario in Revenue by Region: 2015-2020
3.3 North America Angiotensin Converting Enzyme (ACE) Inhibitors Market Facts & Figures by Country
3.3.1 North America Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country
3.3.2 North America Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Angiotensin Converting Enzyme (ACE) Inhibitors Market Facts & Figures by Country
3.4.1 Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country
3.4.2 Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Market Facts & Figures by Region
3.5.1 Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Region
3.5.2 Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Angiotensin Converting Enzyme (ACE) Inhibitors Market Facts & Figures by Country
3.6.1 Latin America Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country
3.6.2 Latin America Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country
3.6.3 Mexico
3.6.3 Brazil
3.6.3 Argentina
3.7 Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Market Facts & Figures by Country
3.7.1 Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country
3.7.2 Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E 4 Global Angiotensin Converting Enzyme (ACE) Inhibitors Historic Market Analysis by Type
4.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Type (2015-2020)
4.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Type (2015-2020)
4.3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Price Market Share by Type (2015-2020)
4.4 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Global Angiotensin Converting Enzyme (ACE) Inhibitors Historic Market Analysis by Application
5.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Application (2015-2020)
5.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Application (2015-2020)
5.3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Price by Application (2015-2020) 6 Company Profiles and Key Figures in Angiotensin Converting Enzyme (ACE) Inhibitors Business
6.1 Abbott Laboratories
6.1.1 Corporation Information
6.1.2 Abbott Laboratories Description, Business Overview and Total Revenue
6.1.3 Abbott Laboratories Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue and Gross Margin (2015-2020)
6.1.4 Abbott Laboratories Products Offered
6.1.5 Abbott Laboratories Recent Development
6.2 Pfizer
6.2.1 Pfizer Corporation Information
6.2.2 Pfizer Description, Business Overview and Total Revenue
6.2.3 Pfizer Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue and Gross Margin (2015-2020)
6.2.4 Pfizer Products Offered
6.2.5 Pfizer Recent Development
6.3 Novartis
6.3.1 Novartis Corporation Information
6.3.2 Novartis Description, Business Overview and Total Revenue
6.3.3 Novartis Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue and Gross Margin (2015-2020)
6.3.4 Novartis Products Offered
6.3.5 Novartis Recent Development
6.4 Merck
6.4.1 Merck Corporation Information
6.4.2 Merck Description, Business Overview and Total Revenue
6.4.3 Merck Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue and Gross Margin (2015-2020)
6.4.4 Merck Products Offered
6.4.5 Merck Recent Development
6.5 Astra Zeneca
6.5.1 Astra Zeneca Corporation Information
6.5.2 Astra Zeneca Description, Business Overview and Total Revenue
6.5.3 Astra Zeneca Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue and Gross Margin (2015-2020)
6.5.4 Astra Zeneca Products Offered
6.5.5 Astra Zeneca Recent Development
6.6 Jhonson and Johnson
6.6.1 Jhonson and Johnson Corporation Information
6.6.2 Jhonson and Johnson Description, Business Overview and Total Revenue
6.6.3 Jhonson and Johnson Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue and Gross Margin (2015-2020)
6.6.4 Jhonson and Johnson Products Offered
6.6.5 Jhonson and Johnson Recent Development
6.7 Eli Lilly
6.6.1 Eli Lilly Corporation Information
6.6.2 Eli Lilly Description, Business Overview and Total Revenue
6.6.3 Eli Lilly Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue and Gross Margin (2015-2020)
6.4.4 Eli Lilly Products Offered
6.7.5 Eli Lilly Recent Development
6.8 Sanofi
6.8.1 Sanofi Corporation Information
6.8.2 Sanofi Description, Business Overview and Total Revenue
6.8.3 Sanofi Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue and Gross Margin (2015-2020)
6.8.4 Sanofi Products Offered
6.8.5 Sanofi Recent Development
6.9 Bristol-Myers Squibb
6.9.1 Bristol-Myers Squibb Corporation Information
6.9.2 Bristol-Myers Squibb Description, Business Overview and Total Revenue
6.9.3 Bristol-Myers Squibb Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue and Gross Margin (2015-2020)
6.9.4 Bristol-Myers Squibb Products Offered
6.9.5 Bristol-Myers Squibb Recent Development
6.10 Bayer
6.10.1 Bayer Corporation Information
6.10.2 Bayer Description, Business Overview and Total Revenue
6.10.3 Bayer Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue and Gross Margin (2015-2020)
6.10.4 Bayer Products Offered
6.10.5 Bayer Recent Development
6.11 GSK
6.11.1 GSK Corporation Information
6.11.2 GSK Angiotensin Converting Enzyme (ACE) Inhibitors Description, Business Overview and Total Revenue
6.11.3 GSK Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue and Gross Margin (2015-2020)
6.11.4 GSK Products Offered
6.11.5 GSK Recent Development
6.12 Teva Pharmaceutical
6.12.1 Teva Pharmaceutical Corporation Information
6.12.2 Teva Pharmaceutical Angiotensin Converting Enzyme (ACE) Inhibitors Description, Business Overview and Total Revenue
6.12.3 Teva Pharmaceutical Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue and Gross Margin (2015-2020)
6.12.4 Teva Pharmaceutical Products Offered
6.12.5 Teva Pharmaceutical Recent Development 7 Angiotensin Converting Enzyme (ACE) Inhibitors Manufacturing Cost Analysis
7.1 Angiotensin Converting Enzyme (ACE) Inhibitors Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Raw Materials Price Trend
7.1.3 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Angiotensin Converting Enzyme (ACE) Inhibitors
7.4 Angiotensin Converting Enzyme (ACE) Inhibitors Industrial Chain Analysis 8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Angiotensin Converting Enzyme (ACE) Inhibitors Distributors List
8.3 Angiotensin Converting Enzyme (ACE) Inhibitors Customers 9 Market Dynamics
9.1 Market Trends
9.2 Opportunities and Drivers
9.3 Challenges
9.4 Porter's Five Forces Analysis 10 Global Market Forecast
10.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Angiotensin Converting Enzyme (ACE) Inhibitors by Type (2021-2026)
10.1.2 Global Forecasted Revenue of Angiotensin Converting Enzyme (ACE) Inhibitors by Type (2021-2026)
10.2 Angiotensin Converting Enzyme (ACE) Inhibitors Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Angiotensin Converting Enzyme (ACE) Inhibitors by Application (2021-2026)
10.2.2 Global Forecasted Revenue of Angiotensin Converting Enzyme (ACE) Inhibitors by Application (2021-2026)
10.3 Angiotensin Converting Enzyme (ACE) Inhibitors Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Angiotensin Converting Enzyme (ACE) Inhibitors by Region (2021-2026)
10.3.2 Global Forecasted Revenue of Angiotensin Converting Enzyme (ACE) Inhibitors by Region (2021-2026)
10.4 North America Angiotensin Converting Enzyme (ACE) Inhibitors Estimates and Projections (2021-2026)
10.5 Europe Angiotensin Converting Enzyme (ACE) Inhibitors Estimates and Projections (2021-2026)
10.6 Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Estimates and Projections (2021-2026)
10.7 Latin America Angiotensin Converting Enzyme (ACE) Inhibitors Estimates and Projections (2021-2026)
10.8 Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Estimates and Projections (2021-2026) 11 Research Finding and Conclusion 12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Contact Us:-

QY Research, INC.
17890 Castleton,
Suite 218,
Los Angeles, CA – 91748
USA: +1 626 295 2442
Email:
enquiry@qyresearch.com

Web:
http://www.qyresearch.com

-

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Angiotensin Converting Enzyme (ACE) Inhibitors Market is Booming Worldwide By Top Key Players: Abbott Laboratories, Pfizer, Novartis, Merck, Astra Zeneca, Jhonson and Johnson, Eli Lilly, Sanofi, Bristol-Myers Squibb, Bayer, GSK, Teva Pharmaceutical here

News-ID: 2141332 • Views:

More Releases from QY Research

Tea Drink Flavor Syrups Market to Reach USD 3,056 Million by 2031 Top 10 Company Globally
Tea Drink Flavor Syrups Market to Reach USD 3,056 Million by 2031 Top 10 Company …
The tea drink flavor syrups industry supplies concentrated flavored liquid formulations used by cafés, tea houses, foodservice operators, beverage manufacturers and retail customers to create flavored hot and cold tea drinks, bubble teas, ready-to-drink (RTD) blends and dessert/beverage applications. These syrups range from single-flavor cane-sugar-based concentrates to premium natural-ingredient and specialty formulations (e.g., floral, fruit, botanical and functional blends), and the market serves both the foodservice channel and industrial/packaged beverage
Hot Chocolate Powder Market to Reach USD 618 Million by 2031 Top 10 Company Globally
Hot Chocolate Powder Market to Reach USD 618 Million by 2031 Top 10 Company Glob …
The global hot chocolate powder industry represents one of the most resilient and emotionally driven segments within the broader powdered beverage market, shaped by strong consumer nostalgia, seasonal consumption patterns, and the growing appeal of indulgent comfort drinks across both mature and emerging economies. Traditionally viewed as a household staple in Western markets, hot chocolate powder has increasingly embedded itself into Asian and Southeast Asian consumption culture due to rising
Grass Fed Chicken Market to Reach CAGR 15% by 2031 Top 10 Company Globally
Grass Fed Chicken Market to Reach CAGR 15% by 2031 Top 10 Company Globally
Grass-fed / pasture-raised chicken occupies a premium niche inside the broader poultry sector, appealing to consumers who prioritise animal welfare, perceived nutritional benefits and environmental practices. Demand is driven by rising middle-class incomes, urban consumers willing to pay a premium for traceability and clear labeling, and by food-service and retail channels that use pasture-raised claims to differentiate products. Investors and producers are paying special attention to standards and certification because
Driving Next-Gen Chip Reliability: How Advanced Silicon Nitride Precursors Are Transforming 3D Semiconductor Manufacturing
Driving Next-Gen Chip Reliability: How Advanced Silicon Nitride Precursors Are T …
ROHM Co., Ltd., a semiconductor components manufacturer in Japan faced recurring defects in LPCVD silicon nitride (Si3N4) films used for passivation and dielectric layers on advanced logic wafers. Conventional gas-phase precursors such as dichlorosilane (DCS) and ammonia resulted in high hydrogen content, variable film stress, and suboptimal step coverage in high-aspect-ratio features, leading to microcracks and dielectric reliability issues. To solve this, the company transitioned to Liquid and Low-Chlorine Silicon

All 5 Releases


More Releases for Angiotensin

Innovative Product Solution In The Angiotensin Receptor Blockers Market Industry …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Angiotensin Receptor Blockers (ARBs) Market Size Valuation Forecast: What Will the Market Be Worth by 2025? Growth has been consistently noted in the angiotensin receptor blockers (arbs) market size in the past few years. The market will see an increase from $8.51 billion in 2024 to $8.78 billion in
Angiotensin Converting Enzyme (ACE) Inhibitors Market
Angiotensin Converting Enzyme (ACE) inhibitors are a class of pharmaceutical drugs used primarily for the treatment of high blood pressure (hypertension), heart failure, and chronic kidney diseases. These medications help to relax blood vessels, thereby lowering blood pressure and improving heart function. ACE inhibitors block the activity of the enzyme that converts angiotensin I to angiotensin II, a peptide that narrows blood vessels. By inhibiting this conversion, ACE inhibitors enable
Angiotensin Converting Enzyme (ACE) Inhibitors Market: An Overview
Angiotensin Converting Enzyme (ACE) inhibitors are a class of medications widely used in the treatment of various cardiovascular conditions, primarily high blood pressure (hypertension) and heart failure. These drugs work by blocking the action of the enzyme angiotensin-converting enzyme, which is responsible for producing a substance called angiotensin II. Angiotensin II constricts blood vessels and raises blood pressure. By inhibiting this enzyme, ACE inhibitors help relax blood vessels, lower blood
Prominent Angiotensin Receptor Blockers (ARBs) Market Trend for 2025: Innovative …
What market dynamics are playing a key role in accelerating the growth of the angiotensin receptor blockers (arbs) market? The upward trend of cardiovascular diseases is predicted to fuel advancements in the angiotensin receptor blockers market. Often related to the accumulation of fatty components within the arteries (atherosclerosis) and heightened probability of blood clots, cardiovascular disease (CVD) influences the heart or blood vessels. The function of angiotensin receptor blockers is to
Angiotensin Receptor Blockers (ARBs) Market Size and Forecast
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global Angiotensin Receptor Blockers (ARBs) Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion. The Angiotensin Receptor Blockers (ARBs) market has been expanding steadily due to their widespread use in the treatment of hypertension, heart failure, and
Angiotensin Receptor Blockers (ARBs) Market 2022 | Detailed Report
The top-notch information research report published by markets and markets is a vital asset that offers qualitative and quantitative factors of the Angiotensin Receptor Blockers (ARBs) market. The research study and methodologies mentioned in the report examine the critical vendors by considering their contribution to the global market. Furthermore, the report offers an in-depth insight into leading players' performance based on revenue generation and client requirements. Also, the research report